Galecto rises on completing dosing for lung disease drug trial

Damora Therapeutics

23/05/2023 17:22

** Shares of drug developer Galecto Inc  GLTO.O  rise 2.3%
to $2.72
    ** Company completes dosing of patients in its trial of
GB0139 for the treatment of a serious lung disease
    ** The mid-stage study is designed to investigate the safety
and efficacy of GB0139 in patients with idiopathic pulmonary
fibrosis, which causes scar tissue to build up in the lungs
    ** Company plans to report top line data from the study in
August 2023
    ** Stock has more than doubled YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))